Danske Bank’s Kyntra Bio KYNB Stock Holding History

Danske Bank’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8	Hold	1	–	–	﹤0.01%	1072
2026 Q1	$7	Hold	1	–	–	﹤0.01%	1093
2025 Q4	$9	Hold	1	–	–	﹤0.01%	1484
2025 Q3	$12	Hold	1	–	–	﹤0.01%	1413
2025 Q2	$5	Buy	+1	New	+$7	﹤0.01%	1477

Other funds holding KYNB

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Danske Bank's KYNB Position: Q2 2026 in Review

Danske Bank held its Kyntra Bio (KYNB) position steady in Q2 2026 at 1 share worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Danske Bank first reported a position in KYNB in Q2 2025 and has held it in 5 quarters since. The position peaked at $12 in Q3 2025. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

Danske Bank held 1 share of Kyntra Bio worth $8 as of Q2 2026.
Danske Bank left its Kyntra Bio share count unchanged in Q2 2026.
Kyntra Bio made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1072 holding.
Danske Bank first reported a position in Kyntra Bio in Q2 2025 and has held it in 5 quarters since.
Danske Bank's Kyntra Bio position peaked at $12 in Q3 2025.
27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.